Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.37 |
| ▸ | CIT | O14578 | 6/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TPH1 | P17752 | 6/20 | 0.41 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.38 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL539367 | 1.00 | CIT (0.45) | CITALDH1A1TPH1ITGA4ITGB7 | |
| Hydrochloric Acid SCHEMBL31206084 | 1.00 | CIT (0.45) | CITALDH1A1TPH1ITGA4ITGB7 | |
| SCHEMBL30167503 | 0.99 | CIT (0.45) | CITALDH1A1TPH1ITGA4ITGB7 | |
| SCHEMBL3629762 | 0.99 | CIT (0.45) | CITALDH1A1TPH1ITGA4ITGB7 | |
| SCHEMBL539489 | 0.99 | CIT (0.45) | CITALDH1A1TPH1ITGA4ITGB7 | |
| Hydrochloric Acid SCHEMBL29106517 | 0.86 | SLC7A5 (0.48) | TPH1PTGS2KDM4EPDCD1CD274 | |
| Hydrochloric Acid SCHEMBL29106516 | 0.86 | SLC7A5 (0.48) | TPH1PTGS2KDM4EPDCD1CD274 | |
| SCHEMBL26706405 | 0.86 | CIT (0.42) | CITTPH1PDCD1CD274 | |
| SCHEMBL26706360 | 0.85 | KDM4E (0.40) | CITALDH1A1ITGA4ITGB7KDM4E | |
| SCHEMBL24073155 | 0.85 | SLC7A5 (0.49) | CITTPH1PTGS2KDM4EPDCD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115667219-A | Preparation method of (S) -2-amino-3- (4- (2,3-dimethylpyridine-4-yl) phenyl) methyl propionate diacid salt | 杭州中美华东制药有限公司 | 2023-01-31 | — | — | CN | disclosed |
| US-9175003-B2 | Substituted azoanthracene derivatives and intermediates for preparation thereof | VTV THERAPEUTICS LLC (US) | 2015-11-03 | — | — | US | disclosed |
| EP-2413693-B1 | SUBSTITUTED AZOANTHRACENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | VTV THERAPEUTICS LLC (US) | 2015-09-09 | — | — | EP | disclosed |
| US-20150148539-A1 | Substituted Azoanthracene Derivatives and Intermediates for Preparation Thereof | VTV THERAPEUTICS LLC | 2015-05-28 | — | — | US | disclosed |
| US-8987295-B2 | Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof | TRANSTECH PHARMA, LLC (US) | 2015-03-24 | — | — | US | disclosed |
| CN-102378574-B | Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof | TRANSTECH PHARMA INC | 2013-11-20 | — | — | CN | disclosed |
| US-20130096150-A1 | Substituted Azoanthracene Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | TRANSTECH PHARMA, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-8383644-B2 | Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof | TRANSTECH PHARMA, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| CN-102378574-A | Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof | TRANSTECH PHARMA INC | 2012-03-14 | — | — | CN | disclosed |
| EP-2413693-A1 | SUBSTITUTED AZOANTHRACENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | TransTech Pharma, Inc (US) | 2012-02-08 | — | — | EP | disclosed |
| US-20110160198-A1 | SUBSTITUTED AZOANTHRACENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-06-30 | — | — | US | disclosed |
| WO-2010114824-A1 | SUBSTITUTED AZOANTHRACENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | TRANSTECH PHARMA INC (US) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096150-A1 | Substituted Azoanthracene Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | GLP1R, GIPR, GPR119 | PTGS2 553/4885CIT 2336/4885ALDH1A1 1899/4885 |
| US-20110160198-A1 | SUBSTITUTED AZOANTHRACENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | GLP1R, GIPR, GPR119 | PTGS2 553/4885CIT 2336/4885ALDH1A1 1899/4885 |
| US-20150148539-A1 | Substituted Azoanthracene Derivatives and Intermediates for Preparation Thereof | GLP1R, GIPR, GPR119 | PTGS2 652/4885CIT 2873/4885ALDH1A1 737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.